Status:
UNKNOWN
Study to Improve the Treatment of Epilepsy (SITE)
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Epilepsy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess whether changing antiepileptic medication can reduce side effects and improve the quality of life in patients with epileptic seizures that are well controlled wi...
Detailed Description
Background. The aim of the treatment with antiepileptic drugs (AEDs) is to achieve seizure freedom without causing side effects. Assessment of side effects is difficult. They may start insidiously, th...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Treatment: antiepileptic drugs for epilepsy
- No change in medication during last 6 months
- No obvious clinical reason to change medication immediately
Exclusion
- Concurrent disease or disorder that might interfere with the conduct of the study
- Inability to comply to the protocol
- Impaired intellectual functioning, leading to inability to comply to the protocol and complete the necessary questionnaires
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00133081
Start Date
October 1 2002
End Date
August 1 2006
Last Update
October 21 2005
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
AZM
Maastricht, Limburg, Netherlands, 6202 AZ
2
Catharina Hospital
Eindhoven, North Brabant, Netherlands, 5623 EJ
3
Hospital Gooi-Noord
Blaricum, North Holland, Netherlands, 1250 CA
4
MCRZ
Rotterdam, South Holland, Netherlands, 3007 AC